| Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer B Englinger, S Kallus, J Senkiv, D Heilos, L Gabler, S van Schoonhoven, ... Journal of Experimental & Clinical Cancer Research 36 (1), 1-13, 2017 | 40 | 2017 |
| Multicenter evaluation of a novel automated rapid detection system of BRAF status in formalin-fixed, paraffin-embedded tissues AI Schiefer, L Parlow, L Gabler, I Mesteri, O Koperek, A Von Deimling, ... The Journal of Molecular Diagnostics 18 (3), 370-377, 2016 | 32 | 2016 |
| TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma L Gabler, D Lötsch, D Kirchhofer, S van Schoonhoven, HM Schmidt, ... Acta neuropathologica communications 7 (1), 1-16, 2019 | 30 | 2019 |
| Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup C Pirker, A Bilecz, M Grusch, T Mohr, B Heidenreich, V Laszlo, ... Clinical Cancer Research 26 (14), 3819-3830, 2020 | 24 | 2020 |
| Cerebrospinal fluid penetration and combination therapy of entrectinib for disseminated ROS1/NTRK-fusion positive pediatric high-grade glioma L Mayr, AS Guntner, S Madlener, MT Schmook, A Peyrl, AA Azizi, ... Journal of personalized medicine 10 (4), 290, 2020 | 23 | 2020 |
| Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib B Englinger, A Laemmerer, P Moser, S Kallus, C Röhrl, C Pirker, D Baier, ... International journal of cancer 147 (6), 1680-1693, 2020 | 22 | 2020 |
| Targeting fibroblast growth factor receptors to combat aggressive ependymoma D Lötsch, D Kirchhofer, B Englinger, L Jiang, K Okonechnikov, D Senfter, ... Acta neuropathologica 142 (2), 339-360, 2021 | 16 | 2021 |
| Human tripartite motif protein 52 is required for cell context-dependent proliferation S Benke, B Agerer, L Haas, M Stöger, A Lercher, L Gabler, I Kiss, ... Oncotarget 9 (17), 13565, 2018 | 16 | 2018 |
| Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness L Gabler, CN Jaunecker, S Katz, S van Schoonhoven, B Englinger, ... Acta Neuropathologica Communications 10 (1), 1-16, 2022 | 10 | 2022 |
| Lysosomal sequestration impairs the activity of the preclinical FGFR inhibitor PD173074 B Englinger, S Kallus, J Senkiv, A Laemmerer, P Moser, L Gabler, ... Cells 7 (12), 259, 2018 | 10 | 2018 |
| p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction C Dinhof, C Pirker, P Kroiss, D Kirchhofer, L Gabler, J Gojo, ... Cancers 12 (11), 3205, 2020 | 8 | 2020 |
| CSIG-04. UNCOUPLING OF ETS1 FROM MAPK PATHWAY SIGNALS AS RESISTANCE MECHANISM TOWARDS BRAF INHIBITORS IN BRAF-MUTATED CHILDHOOD GLIOMA L Gabler, D Lötsch-Gojo, D Kirchhofer, A Laemmerer, L Mayr, C Pirker, ... Neuro-Oncology 23 (Supplement_6), vi33-vi34, 2021 | 1 | 2021 |
| CSIG-30. TARGETING TELOMERASE VIA MEK INHIBITION IN AGGRESSIVE TERT PROMOTER MUTATED BRAIN TUMORS D Lötsch-Gojo, L Gabler, C Jaunecker, K Fürnweger, K Bruckner, L Mayr, ... Neuro-Oncology 23 (Supplement_6), vi39-vi40, 2021 | 1 | 2021 |
| CBIO-22. PARP INHIBITION SYNERGIZES WITH DNA DAMAGING DRUGS IN PEDIATRIC CNS TUMORS A Laemmerer, D Kirchhofer, S Madlener, D Loetsch-Gojo, C Jaunecker, ... Neuro-Oncology 23 (Supplement_6), vi31-vi31, 2021 | | 2021 |
| P04.51 TERT promoter mutation-driven TERT activation is mediated by ETS1 in BRAF V600E mutated glioma L Gabler, J Gojo, D Lötsch, D Kirchhofer, S van Schoonhoven, ... Neuro-Oncology 20 (suppl_3), iii290-iii291, 2018 | | 2018 |
| TERT PROMOTER MUTATION-DRIVEN TERT ACTIVATION IS MEDIATED BY ETS1 IN BRAF V600E MUTATED GLIOMA L Gabler, J Gojo, D Loetsch, D Kirchhofer, S van Schoonhoven, ... NEURO-ONCOLOGY 20, 291-291, 2018 | | 2018 |
